We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cancer Research UK to Fund Clinical Trial of ADXS11-001 for the Treatment of Head and Neck Cancer
News

Cancer Research UK to Fund Clinical Trial of ADXS11-001 for the Treatment of Head and Neck Cancer

Cancer Research UK to Fund Clinical Trial of ADXS11-001 for the Treatment of Head and Neck Cancer
News

Cancer Research UK to Fund Clinical Trial of ADXS11-001 for the Treatment of Head and Neck Cancer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cancer Research UK to Fund Clinical Trial of ADXS11-001 for the Treatment of Head and Neck Cancer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Advaxis, Inc. has announced that Cancer Research UK (CRUK), the UK philanthropy dedicated to cancer research, has agreed to fund the cost of a clinical trial to investigate the use of ADXS11-001, Advaxis’ lead human papilloma virus (HPV)-directed vaccine candidate, for the treatment of head and neck cancer.

This sponsored-clinical trial will investigate the safety and efficacy of ADXS11-001 in head and neck cancer patients who have previously failed treatment with surgery, radiotherapy and chemotherapy – alone or in combination. Advaxis will provide the vaccines with all other associated costs to be funded by CRUK.

The study is to be conducted at Aintree Hospital at the University of Liverpool, Royal Marsden Hospital in London, and Cardiff Hospital at the University of Wales. Patient enrollment is slated for the latter part 2010. At such time, enrollment officials anticipate recruiting a maximum of forty-five (45) patients.

“Both acceptance by the scientific community and interest in collaborating on live, attenuated Listeria vaccines is accelerating,” said Advaxis Executive VP of Science & Operations John Rothman. “The high caliber of collaborating clinical researchers, such as CRUK and NCI, will result in an excellent development programs. The development of new vaccines, at the pre-clinical level, is being spurred by collaborations with such noteworthy institutions as the City of Hope, the Roswell Cancer Institute and the University of Pittsburgh.”
Advertisement